• DOI:10.1136/bmj.38149.566979.AE
Corpus ID: 901001

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

@article{Svendsen2004DoesTC,
  title={Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial},
  author={K. Svendsen and T. Jensen and F. Bach},
  journal={BMJ : British Medical Journal},
  year={2004},
  volume={329},
  pages={253}
}

K. Svendsen, T. Jensen, F. Bach

Published 2004

Medicine

BMJ : British Medical Journal

Abstract Objective To evaluate the effect of the oral synthetic δ-9-tetrahydrocannabinol dronabinol on central neuropathic pain in patients with multiple sclerosis. Design Randomised double blind placebo controlled crossovertrial. Setting Outpatient clinic, University Hospital of Aarhus, Denmark. Participants 24 patients aged between 23 and 55 years with multiple sclerosis and central pain. Intervention Orally administered dronabinol at a maximum doseof 10 mg daily or corresponding placebo for… CONTINUE READING

View on BMJ

bmj.com

Save to Library

Create Alert

Cite

Launch Research Feed